Altimmune names Greg Weaver CFO, with $475k salary and 225k option grant

Altimmune, Inc.

Mr. Weaver appointed CFO effective Nov 11, 2024; previously CFO at atai Life Sciences.
Employment terms: annual salary $475k, target bonus 40%, sign-on option for 225k shares and 75k RSUs.
Andrew Shutterly transitions from Interim CFO to Corporate Controller.
Weaver led $225M IPO at atai Life Sciences and has 25+ years of biotech finance experience.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gregory Weaver

Chief Financial Officer

ALT · Altimmune, Inc.

Effective: 2024-11-11
Filed: November 12, 2024, 6:59 PM ET

On November 11, 2024, Altimmune, Inc. (the “Company”) issued a press release announcing the decision of the Company’s Board of Directors (the “Board”) to appoint Mr. Gregory Weaver as the Company’s Chief Financial Officer (“CFO”), effective November 11, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gregory Weaver was appointed as Chief Financial Officer at Altimmune, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On November 11, 2024, Altimmune, Inc. (the “Company”) issued a press release announcing the decision of the Company’s Board of Directors (the “Board”) to appoint Mr. Gregory Weaver as the Company’s Chief Financial Officer (“CFO”), effective November 11, 2024.

View on SEC.gov

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-24-000046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.